Comparative Gene Expression Profiling Identifies Common Molecular Signatures of NF-κB Activation in Canine and Human Diffuse Large B Cell Lymphoma (DLBCL)

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Mudaliar, Manikhandan A V ^a,f   Haggart, Ross D ^a   Miele, Gino ^b   Sellar, Grant ^b   Tan, Karen A L ^d   Goodlad, John R ^c   Milne, Elspeth ^d   Vail, David M ^e   Kurzman, Ilene ^e   Crowther, Daniel ^b,g   Argyle, David J ^d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPTOTAGMIN I;

ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANINE LYMPHOMA; CONTROLLED STUDY; DOG; DOG DISEASE; GENE EXPRESSION PROFILING; GENE MAPPING; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE; MICROARRAY ANALYSIS; MOLECULAR PROBE; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; ORTHOLOGY; PRINCIPAL COMPONENT ANALYSIS; PROTEIN FUNCTION; SPECIES COMPARISON; TISSUE MICROARRAY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; VALIDATION PROCESS;

ANIMALS; BLOTTING, WESTERN; DOGS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME;

EID: 84883403551     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072591     Document Type: Article

References (51)

1. Gordon I, Paoloni M, Mazcko C, Khanna C, (2009) The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway. PLoS Med. 6(10): e1000161.
2. Adams VJ, Evans KM, Sampson J, Wood JL, (2010) Methods and mortality results of a health survey of purebred dogs in the UK. J Small Anim Pract. 51(10): 512-24.
3. Shearin AL, Ostrander EA, (2010) Leading the way: canine models of genomics and disease. Disease models & mechanisms. 3(1-2): 27-34.
4. Paoloni M, Khanna C, (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 8(2): 147-56.
5. Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, et al. (2009) Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics. 10: 135.
6. Cancer statistics registrations (2010) Available at: http://www.ons.gov.uk/ons/rel/vsob1/cancer-registrations-in-england/2010/2010-cancer-registrations-in-england-statistical-bulletin-2.html (Accessed August 2013).
7. Cancer Incidence in Wales 2003-2007 (2009) Available at: http://www.wales.nhs.uk/sites3/Documents/242/Cancer%20Incidence%20in%20Wales%202003-2007.pdf (Accessed August 2013).
8. Cancer incidence in Scotland (2013) Available at: http://www.isdscotland.org/Health-Topics/Cancer/ (Accessed August 2013).
9. Vail DM, Young KM (2007) Canine Lymphoma and Lymphoid Leukemia. In:. Withrow and MacEwen's small animal clinical oncology, Withrow SJ, Vail DM, (ed) 4ed. London/GB: Elsevier Health Sciences; 2007. p. 699-700.
10. Chan WJ, (2010) Pathogenesis of diffuse large B cell lymphoma. Int J Hematol. 92(2): 219-30.
11. Vallabhapurapu S, Karin M, (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 27: 693-733.
12. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403(6769): 503-11.
13. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, et al. (2005) Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 106(5): 1770-7.
14. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, et al. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100(17): 9991-6.
15. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 346(25): 1937-47.
16. Lenz G, Staudt LM, (2010) Mechanisms of Disease: Aggressive lymphomas. N Engl J Med. 362(15): 1417-29.
17. Rutgen BC, Hammer SE, Gerner W, Christian M, de Arespacochaga AG, et al. (2010) Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma. Leuk Res. 34(7): 932-8.
18. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, et al. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 459(7247): 717-21.
19. Gatto L, Yaqcaffy (2010) Available from: http://bioconductor.org/packages/release/bioc/html/yaqcaffy.html (cited and accessed 20 October 2010).
20. Parman C, Halling C, Gentleman R, affyQCReport (2010) Available from: http://www.bioconductor.org/packages/release/bioc/html/affyQCReport.html (cited and accesses 20 October 2010).
21. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5(10): R80.
22. The R Project for Statistical Computing (2010) Available from: http://www.r-project.org [cited and accessed 20 October 2010].
23. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4(2): 249-64.
24. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31(4): e15.
25. NetAffx Analysis Center (2010) Available from: http://www.affymetrix.com/analysis/index.affx [cited 2010 and Accessed August 2010).
26. Partek (2010) Partek® Genomics SuiteTM Revision 6.5 ed. St. Louis: Partek Inc.
27. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4(1): 44-57.
28. Bolstad B affy (2009) 1.22.1 ed: http://bioconductor.org; (Accessed October 2010).
29. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, et al. (2007) Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2(10): 2366-82.
30. Bader GD, Hogue CW, (2003) An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 4: 2.
31. Ingenuity (2010) Ingenuity Pathways Analysis. 8.7 ed. Redwood City, CA Ingenuity Systems Inc.
32. Chou TC, (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010 Jan 15 70(2): 440-6.
33. Jost PJ, Ruland J, (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109(7): 2700-7.
34. Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A, (2007) The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol). 19(2): 154-61.
35. Karin M, (2006) Nuclear factor-kappaB in cancer development and progression. Nature. 441(7092): 431-6.
36. Karin M, (2008) The IkappaB kinase - a bridge between inflammation and cancer. Cell Res. 18(3): 334-42.
37. Thome M, (2004) CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat Rev Immunol. 4(5): 348-59.
38. Hiscott J, Kwon H, Genin P, (2001) Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest. 107(2): 143-51.
39. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, et al. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 463(7277): 88-92.
40. Brien G, Trescol-Biemont MC, Bonnefoy-Berard N, (2007) Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene. 26(39): 5828-32.
41. Hollmann CA, Owens T, Nalbantoglu J, Hudson TJ, Sladek R, (2006) Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death. Cancer Res 66(7): 3550-7.
42. Paterson JC, Tedoldi S, Craxton A, Jones M, Hansmann ML, et al. (2006) The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. Haematologica. 91(6): 772-80.
43. Zamanian-Daryoush M, Mogensen TH, DiDonato JA, Williams BR, (2000) NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol. 20(4): 1278-90.
44. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, et al. (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature. 470(7332): 115-9.
45. Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Mason NJ, (2011) NEMO-Binding Domain Peptide Inhibits Constitutive NF-kappa B Activity and Reduces Tumor Burden in a Canine Model of Relapsed, Refractory Diffuse Large B-Cell Lymphoma Clinical Cancer Research: 17. 14: 4661-4671.
46. Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, et al. (1995) Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood. 85(2): 500-9.
47. Molina JR, (2008) Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs. 11(7): 508-21.
48. Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, et al. (2010) Predictive factors for anthracycline-based chemotherapy for human breast cancer. Breast Cancer. 17(2): 103-9.
49. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, et al. (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 114(17): 3533-7.
50. Fang C, Xu W, Li JY, (2010) A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. Ann Hematol. 89(11): 1107-13.
51. Frantz AM, Sarver AL, Ito D, Phang TL, Karimpour-Fard A, et al. (2013) Molecular Profiling Reveals Prognostically Significant Subtypes of Canine Lymphoma Vet Pathol, vol. 50 no. 4 693-703.